Silo Pharma Inc. (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, announced that its representatives will participate in the IPAC-RS 2026 Nasal Innovation Forum, scheduled for September 16-17, 2026, in Jersey City, New Jersey. The forum provides a platform for experts in nasal drug development to discuss innovations and challenges, and Silo Pharma's participation highlights its ongoing efforts to advance SPC-15, a novel nose-to-brain approach for targeted drug delivery in the treatment of post-traumatic stress disorder (PTSD).
CEO Eric Weisblum emphasized the importance of engaging with industry experts at the forum as Silo continues to develop SPC-15. The company's participation is a strategic move to stay at the forefront of nasal drug delivery technology and to network with key opinion leaders in the field. This engagement is particularly relevant given the growing interest in alternative routes of drug administration that can enhance bioavailability and patient compliance, especially for central nervous system (CNS) disorders.
The announcement comes on the heels of positive preclinical data for SPC-15. The company reported that the formulation and device met predefined specifications for assay, impurities, pH, and microbiological quality through nine months. Additionally, six-month accelerated stability data was consistent and aligned with long-term data, indicating the product's robustness and potential for commercial viability. These findings are crucial as they demonstrate the stability and quality of SPC-15, which are essential for regulatory approval and eventual commercialization.
The implications of this progress are significant for the biopharmaceutical industry and for patients suffering from PTSD, a condition that affects millions worldwide and has limited effective treatment options. Current treatments often involve oral medications that can have systemic side effects and delayed onset of action. The nose-to-brain delivery route offers a promising alternative, potentially providing faster relief and reducing systemic exposure. If successful, SPC-15 could revolutionize PTSD management and pave the way for similar approaches for other CNS disorders.
Silo Pharma's participation in the forum also underscores the increasing convergence of technology and biopharmaceuticals. As a company with a wholly owned managed AI agent platform, Silo is leveraging artificial intelligence to streamline drug development processes, from formulation to data analysis. This integration of AI is expected to accelerate the discovery and development of new therapies, reduce costs, and improve success rates. The company's innovative approach is a testament to the transformative potential of AI in healthcare.
The IPAC-RS forum is a respected event that attracts leaders in nasal drug delivery, including representatives from regulatory agencies, academia, and industry. Silo's presence at the forum will allow it to showcase its scientific advancements, gain insights into regulatory expectations, and explore potential collaborations. This is particularly important as the company moves forward with its clinical development plans and seeks to bring SPC-15 to market.
For more information about Silo Pharma and its pipeline, visit the company's website at silopharma.com. For the latest news and updates on SILO, refer to the company's newsroom at https://ibn.fm/SILO.
As Silo Pharma continues to progress its innovative therapies, the industry and investors will be watching closely. The company's focus on underserved conditions and its use of advanced drug delivery systems position it as a potential leader in the next wave of psychiatric and neurological treatments.
